(UroToday.com) There are multiple ongoing salvage intravesical therapy trials for patients with non-muscle invasive bladder cancer who do not respond to Bacillus Calmette-Guérin (BCG). However, oncologic outcomes for patients who fail salvage intravesical therapy are not well established. At the American Urological Association (AUA) 2020 Virtual Meeting, Vignesh Packiam, MD, and colleagues presented results of their evaluation of the impact of salvage intravesical therapy on survival in patients with non-muscle invasive bladder cancer previously treated with BCG who ultimately underwent radical cystectomy. 

X